| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TAGLN2 |
| Uniprot No | P37802 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-199aa |
| 氨基酸序列 | ANRGPAYGL SREVQQKIEK QYDADLEQIL IQWITTQCRK DVGRPQPGRE NFQNWLKDGT VLCELINALY PEGQAPVKKI QASTMAFKQM EQISQFLQAA ERYGINTTDI FQTVDLWEGK NMACVQRTLM NLGGLAVARD DGLFSGDPNW FPKKSKENPR NFSDNQLQEG KNVIGLQMGT NRGASQAGMT GYGMPRQIL |
| 预测分子量 | 26kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TAGLN2重组蛋白的3篇参考文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**: *"Recombinant TAGLN2 suppresses breast cancer cell metastasis via regulation of cytoskeleton remodeling"*
**作者**: Zhao, L., et al.
**摘要**: 研究通过在大肠杆菌中表达重组TAGLN2蛋白，发现其通过结合肌动蛋白抑制细胞骨架重构，从而降低乳腺癌细胞的迁移和侵袭能力，提示其在肿瘤转移中的潜在调控作用。
2. **文献名称**: *"Prokaryotic expression and functional analysis of TAGLN2 in macrophage inflammatory response"*
**作者**: Kim, S., & Park, H.
**摘要**: 利用原核系统表达并纯化TAGLN2重组蛋白，发现其通过调节巨噬细胞中炎症信号通路(如NF-κB)影响细胞因子的分泌，为TAGLN2在免疫炎症中的功能提供依据。
3. **文献名称**: *"Crystal structure of human TAGLN2 reveals a conserved actin-binding domain"*
**作者**: Watanabe, T., et al.
**摘要**: 通过重组表达人源TAGLN2蛋白并解析其晶体结构，鉴定出一个高度保守的肌动蛋白结合域，为揭示TAGLN2在细胞运动中的分子机制提供结构基础。
---
*注：上述文献为示例性质，实际研究中请以具体数据库(如PubMed、Web of Science)检索结果为准。若需全文链接或更多文献，可进一步限定研究领域(如肿瘤、免疫或结构生物学)。*
**Background of TAGLN2 Recombinant Protein**
Transgelin-2 (TAGLN2) is a 22-kDa actin-binding protein belonging to the calponin-transgelin family, widely expressed in smooth muscle cells, fibroblasts, and immune cells. It plays a critical role in modulating cytoskeletal dynamics, cell motility, and contractile processes by stabilizing actin filaments and interacting with other cytoskeletal regulators. TAGLN2 is implicated in various physiological and pathological processes, including immune response regulation, vascular remodeling, and cancer progression. Studies highlight its involvement in T-cell activation, macrophage migration, and endothelial cell function, suggesting its importance in inflammation and immune-related disorders.
Recombinant TAGLN2 protein is engineered using expression systems like *E. coli* or mammalian cell lines to produce high-purity, functional protein for research and therapeutic applications. Its recombinant form often includes affinity tags (e.g., His-tag) for simplified purification and detection. This tool enables mechanistic studies of TAGLN2's interactions with binding partners, post-translational modifications, and signaling pathways.
In cancer research, TAGLN2 is studied for its dual roles: it may act as a tumor suppressor by inhibiting cell proliferation or as an oncogene by promoting metastasis via epithelial-mesenchymal transition (EMT). Dysregulation of TAGLN2 is linked to cancers such as glioblastoma, breast cancer, and hepatocellular carcinoma. Additionally, its overexpression in cardiovascular diseases correlates with vascular smooth muscle cell dysfunction and atherosclerosis.
Current research focuses on clarifying TAGLN2's context-dependent functions, tissue-specific isoforms, and therapeutic targeting. Recombinant TAGLN2 facilitates drug screening, biomarker development, and structural studies to design inhibitors or activators for disease intervention. Despite progress, challenges remain in understanding its pleiotropic effects and translational potential across diverse pathologies.
×
